Revvity, Inc traded at $154.39 this Friday November 13th, decreasing $2.63 or 1.67 percent since the previous trading session. Looking back, over the last four weeks, Revvity lost 1.49 percent. Over the last 12 months, its price rose by 66.49 percent. Looking ahead, we forecast Revvity, Inc to be priced at 151.79 by the end of this quarter and at 142.25 in one year, according to Trading Economics global macro models projections and analysts expectations.
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and Haoyuan.